India to Brazil: Amoxicillin Export Trade Route

To import finished pharmaceutical formulations containing Amoxicillin into Brazil, the following approvals and registrations are mandatory:

• Marketing Authorization (MA): All pharmaceutical products must obtain a Marketing Authorization from ANVISA before commercialization. This involves submitting a comprehensive dossier that includes data on product quality, safety, and efficacy. The dossier should be formatted according to the Common Technical Document (CTD) or electronic CTD (eCTD) standards.

• Local Representation: Foreign manufacturers must appoint a legally established partner company in Brazil to act as the local representative. This entity assumes legal responsibility for the imported products and handles all interactions with ANVISA.

• Good Manufacturing Practices (GMP) Certification: Manufacturing facilities producing the Amoxicillin formulations must comply with ANVISA's GMP standards. This compliance is verified through inspections conducted by ANVISA or recognized equivalent authorities.

• Import License: The Brazilian importer must possess a valid import license issued by ANVISA, authorizing the importation of pharmaceutical products.

Indian manufacturers exporting Amoxicillin formulations to Brazil must adhere to the following quality and GMP standards:

• GMP Certification: Facilities must obtain GMP certification from ANVISA, confirming compliance with Brazilian regulatory standards. This certification is valid for two years from the date of issuance.

• Inspection Requirements: ANVISA conducts inspections of foreign manufacturing sites to ensure GMP compliance. These inspections can be on-site or based on documentation, depending on ANVISA's assessment.

• Recent Certifications:
• In July 2025, Akums Drugs & Pharmaceuticals Ltd. received ANVISA GMP certification for its sterile manufacturing facility in Haridwar, India.
• In January 2026, Naprod Life Sciences Pvt. Ltd. renewed its ANVISA GMP certification for its Tarapur manufacturing facility following a successful inspection in July 2025.

Several regulatory changes and developments have occurred in the past 18 months affecting pharmaceutical exports to Brazil:

• Regulatory Reliance Mechanisms: In 2024, ANVISA implemented reliance mechanisms to streamline the approval process by accepting inspection reports and certifications from authorities that are members of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

• Updated GMP Regulations: In 2022, ANVISA updated its GMP regulations to align with international standards, enhancing the quality and safety of pharmaceutical products in Brazil.

These developments aim to facilitate the importation process while ensuring that imported pharmaceutical products meet Brazil's stringent quality and safety standards.

TARIFF_NOTES: Pharmaceutical products, including formulations containing Amoxicillin, are generally exempt from import duties in Brazil.

In 2024, the Brazilian antibiotics market was valued at approximately USD 774.5 million, with projections indicating growth to USD 964.3 million by 2033, reflecting a compound annual growth rate (CAGR) of 2.4% from 2025 to 2033. Amoxicillin, a widely used antibiotic, constitutes a significant portion of this market. The demand for Amoxicillin formulations in Brazil is driven by factors such as the prevalence of bacterial infections, increased healthcare spending, an aging population, and the country's commitment to universal health coverage. While Brazil has domestic pharmaceutical manufacturing capabilities, the country also relies on imports to meet its Amoxicillin demand, sourcing finished formulations from international suppliers, including those in India.

Brazil's import duty structure for pharmaceutical products under HS code 30041030 is as follows:

• Import Duty (II): 0%
• Industrialized Product Tax (IPI): Varies; typically ranges from 0% to 15%, depending on the product's classification and essentiality.
• Federal Social Contribution Taxes (PIS/COFINS): Combined rate of approximately 11.75%, calculated on the sum of the CIF value, import duty, and IPI.
• Merchandise and Service Circulation Tax (ICMS): State-level tax with rates varying by state; commonly around 17%.

These taxes are calculated cumulatively, with each subsequent tax applied to the sum of the CIF value and previously assessed taxes. Brazil and India are both members of the World Trade Organization (WTO) and the BRICS group; however, there is no specific Free Trade Agreement (FTA) between the two countries that affects pharmaceutical tariffs. Additionally, there are no anti-dumping duties imposed on Amoxicillin formulations imported from India.

India is a major supplier of Amoxicillin formulations to Brazil, accounting for a significant portion of the country's imports. Other notable suppliers include China and European Union (EU) member states. India's share of Brazil's total Amoxicillin imports is substantial, reflecting the strong trade relations between the two countries in the pharmaceutical sector. Pricing of Indian Amoxicillin formulations is generally competitive compared to products from China and EU manufacturers, offering cost advantages without compromising quality. This competitive pricing, combined with India's robust pharmaceutical manufacturing capabilities, positions Indian exporters favorably in the Brazilian market.

India is a global leader in the production of generic pharmaceuticals, including formulations containing Amoxicillin. As of 2024, the country hosts 752 FDA-approved manufacturing sites and 2,050 WHO-GMP-certified plants, the highest globally. This extensive infrastructure enables large-scale production of finished dosage forms such as tablets, capsules, and syrups. Indian manufacturers benefit from cost-effective operations due to economies of scale, competitive labor costs, and a well-established supply chain. Notably, companies like Dr. Reddy's Laboratories maintain 23 manufacturing facilities worldwide, all compliant with USFDA regulations as of March 31, 2024.

When comparing Amoxicillin formulations from India, China, and the European Union, several factors emerge:

• Cost: Indian manufacturers offer competitive pricing for generic formulations, balancing affordability with quality. Chinese suppliers may provide lower prices but often face scrutiny regarding GMP compliance. EU manufacturers, while adhering to stringent quality standards, typically have higher production costs, resulting in more expensive products.

• Quality Perception: Indian pharmaceutical companies have invested significantly in meeting international quality standards, with numerous facilities approved by regulatory bodies such as the USFDA and WHO. Chinese manufacturers have made strides in quality but may still encounter perceptions of inconsistency. EU manufacturers are generally regarded as producing high-quality products due to strict regulatory oversight.

• Regulatory Acceptance in Brazil: Brazil's regulatory agency, ANVISA, recognizes certifications from international bodies like the USFDA and WHO. Indian manufacturers' compliance with these standards facilitates smoother market entry into Brazil. Chinese and EU manufacturers must also meet ANVISA's requirements, but Indian companies' established track record provides an advantage.

• Supply Reliability: Indian pharmaceutical companies have demonstrated a reliable supply track record, supported by robust manufacturing capacities and established export channels. Chinese suppliers may offer rapid production but can face challenges related to regulatory compliance and supply chain disruptions. EU manufacturers provide high-quality products but may have longer lead times and higher costs.

The India-Brazil supply chain for Amoxicillin formulations is robust, underpinned by India's substantial manufacturing capacity and compliance with international regulatory standards. Indian facilities are equipped with advanced packaging and cold chain capabilities, ensuring product integrity during transit. As of November 11, 2025, Granules India Limited's subsidiary, Granules Life Sciences Private Limited, received U.S. FDA approval for its Hyderabad facility, marking a significant expansion in finished dosage manufacturing capabilities. This development indicates ongoing capacity enhancements among top Indian manufacturers.

For Brazilian buyers sourcing Amoxicillin formulations from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks related to supply disruptions and ensure consistent product availability.

• Minimum Order Quantities (MOQs): Indian suppliers may have MOQs ranging from 5,000 to 50,000 units, depending on the product and manufacturer. Negotiating MOQs that align with your demand forecasts can optimize inventory management.

• Payment Terms: Common payment terms in India-Brazil pharmaceutical trade include letters of credit (LC) and advance payments. Establishing clear payment agreements upfront can facilitate smooth transactions.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits, verification of regulatory certifications (e.g., USFDA, WHO-GMP), and assessment of quality control systems. This ensures compliance with Brazilian regulatory standards and product quality expectations.

• Regulatory Compliance: Ensure that selected suppliers have a history of compliance with international regulatory bodies and possess the necessary certifications recognized by ANVISA.

By implementing these strategies, Brazilian buyers can establish a reliable and cost-effective supply chain for Amoxicillin formulations from India.

By adhering to these guidelines, Brazilian companies can effectively qualify Indian suppliers of Amoxicillin formulations, ensuring compliance with regulatory standards and the delivery of high-quality pharmaceutical products.